Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
about
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysisClinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-AnalysisMicro-RNAs, New performers in multiple myeloma bone marrow microenvironmentDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Development of Novel Immunotherapies for Multiple MyelomaMesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor MicroenvironmentNovel therapeutic strategies for multiple myelomaImmune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignanciesSurvivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Enhancing cytokine-induced killer cell therapy of multiple myeloma.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.The targeting of immunosuppressive mechanisms in hematological malignancies.Targeting the bone marrow microenvironment in multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Novel Immunotherapies for Multiple Myeloma.The potential diagnostic power of extracellular vesicle analysis for multiple myeloma.PD-L1-specific T cells.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Anti-regulatory T cells.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.Microenvironment drug resistance in multiple myeloma: emerging new players.Targeting the Bone Marrow Microenvironment.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionThe multi-faceted potential of CD38 antibody targeting in multiple myeloma.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 TherapyOsteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
P2860
Q26775460-1776A539-1BD1-4B84-AB00-4EFCAC48BE4FQ26778025-9E54993E-7D80-4E1C-BD06-1B0555B0D074Q26823660-F1C494E0-8E18-4AF7-948F-6CC862023BEDQ27692033-20337D1A-4279-47ED-A830-07FDCE4EC1D2Q28066890-688978EF-EAC5-405A-8095-460CFD6D4334Q28073613-55E22BFC-54AE-4FFA-854C-95A5B8D00FD0Q28081590-22CF792E-7BEB-43D4-8515-50DE31A12540Q33638083-EC1121F2-A40E-4A5D-B24F-08076EFB2F9AQ33651495-3C211020-7337-4CB3-A8D2-427E7CCB0FD0Q35623772-A26EF905-8355-4324-A87E-16C2A8670CBFQ36813010-5FAB7049-29CB-4A55-AA77-2EEDF5A703BDQ36892290-B0312ECB-316C-4240-A8B2-06A82C03CC01Q37035836-F440F38B-6672-4B14-AA5F-E2243B0A934FQ37381288-4E87AAFE-D797-4F4F-B818-F2E059BE85EBQ37462524-1A254185-32FD-4109-B110-698898881A4DQ37641801-83BDC7EB-C822-417A-9593-9157EA6BC331Q38155039-D15C76B5-D89F-4690-A092-E8D5B95A80A3Q38201231-9A312ABC-7015-4D20-86F8-A12FE798E38CQ38289041-4863FB73-4D5B-4D84-BD80-6F3767E0F06BQ38370539-A2FF4E5E-9C06-47FA-9AC6-C06B41F711D5Q38640444-E23CDAD1-3BEF-4833-A6DE-00E0704E940BQ38670495-84894E00-3037-4B98-87EA-690225456A68Q38685359-20F7EA82-2D47-4590-9FFC-B34316D81789Q38704573-4008C753-9621-450F-A48C-E113EDA2D956Q38765760-53666F1D-4202-4381-83ED-2F5E4153A790Q38792725-AFD0A74A-B7C1-426B-9183-3932E9484ABCQ38817090-01F9D73A-0621-4B26-8D46-BA7679A534A9Q38853857-B758D44F-521D-46CE-A813-1DFEDD3D21CAQ38874291-F1E8B9E2-9C77-4A90-9F44-09F7FAC585C8Q38913083-4332D355-CCCC-4BA4-ACC6-87136D3262A0Q38970585-93997734-05A8-40BE-8525-60DBB321B1A0Q38996724-3CCF49A1-E485-4189-90CF-048E7DA8EA3DQ39093915-36D84674-9549-4D7F-A16D-BCD99534F270Q39136762-722B584D-5CE5-4AC1-926D-837B42110B17Q39200031-DB3992B0-8442-45DB-AC11-25C95849BE0CQ39420466-6DA7DBE9-F225-4F5A-ABA4-A4234A32C886Q41153847-419B9C3E-3246-4A1C-BE1C-D38EE9EC69F1Q41168758-B164C729-AE2F-49C9-8433-32B18D35C754Q41578214-01D48599-2458-4D02-BEB8-275438DE818FQ41770950-8B6C6E57-B605-45FB-AF9E-766234C0CEB1
P2860
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@en
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@nl
type
label
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@en
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@nl
prefLabel
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@en
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@nl
P2093
P2860
P356
P1433
P1476
Marrow stromal cells induce B7 ...... teristics in multiple myeloma.
@en
P2093
H Takahashi
P2860
P2888
P304
P356
10.1038/LEU.2012.213
P577
2012-07-25T00:00:00Z